In this week’s EuroBiotech Report, Johnson & Johnson added another outpost to its burgeoning network of startup-scouting units. The J&J-Karolinska Institutet alliance kicked off a busy week for the Nordic region. And more. …read more Source: J&J sets up shop at Karolinska Institutet; Lilly, Zealand scrap R&D pact; Mapi raises $10M
Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor. …read more Source: Buzz: Cellectis could be in line for a $1.6B Pfizer buyout
What’s a surefire way to build interdisciplinary communication and teamwork at a biotech company? Start a band, according to Momenta Pharmaceuticals CFO Rick Shea. …read more Source: FierceBiotech Radio at the Battle of the Biotech Bands
Wall Street’s recent fervor over biotech companies has hardly been limited to local players, and the allure of handsome valuations and easy access to capital has brought more and more European drug developers across the Atlantic with hopes becoming the next big thing in a boom market. …read more Source: Wall Street’s open for biotech […]
Flush with a new, multibillion-dollar drug franchise, a booming Gilead is now hiring investigators for its fast-growing operations in Canada. The biotech is doubling down on its $100 million R&D investment in Alberta, Canada, with plans to expand on the new lab that opened this week at its Edmonton campus as it hires up to […]
Bavarian Nordic has downplayed its interest in becoming the latest European biotech to be scooped up by a deep-pocketed suitor. The vaccine player has regained some of its luster over the past year through deals with Bristol-Myers Squibb and Johnson & Johnson, but has no desire to cash in on its moment in the limelight. […]
GlobeImmune’s in-development vaccine for hepatitis B missed the mark in a Phase II trial, marring the value of a program licensed to Gilead Sciences. …read more Source: GlobeImmune’s Gilead-partnered hep B vaccine fails in Phase II
Two of the cancer drugs Novartis traded for from GSK–Tafinlar and Mekinist–will post combo survival data at ASCO. …read more Source: Post-swap Novartis preps cancer drug R&D road show
Retrophin is selling its recently acquired coupon for a speedy FDA approval to Sanofi for $245 million in cash. …read more Source: Sanofi splurges $245M on Retrophin’s speedy-review voucher
Bluebird bio, already making headlines with its promising gene therapy, is expanding its efforts in immuno-oncology, pairing up with Five Prime Therapeutics to develop cell therapies for cancer. …read more Source: Bluebird widens its CAR-T ambitions with a $130M Five Prime deal
